EVFM - Evofem announces U.S. patent win for birth control method

• Commercial-stage pharma Evofem Biosciences ( NASDAQ: EVFM ) announced on Thursday that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a certain patent application filed by the company for Phexxi birth control method.
• The application titled "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides" relates to the composition of matter of the FDA-approved contraceptive vaginal gel, the company said.
• A patent for the application 16/738,868 is expected to provide protection for Phexxi into 2033, Evofem ( EVFM ) noted.
• “….this allowance further solidifies the investment Evofem has made in creating Phexxi and providing it to women across the United States," remarked Evofem ( EVFM ) Chief Executive Saundra Pelletier.
• Evofem ( EVFM ) shares surged on Tuesday after the company announced a partnership with one of the largest pharmacy benefit managers for Phexxi.

For further details see: